CA-AQUA-LUNG
11.9.2019 00:27:02 CEST | Business Wire | Press release
Aqua Lung , the celebrated pioneer, designer, manufacturer and distributor of dive and watersports equipment for 75 years, has appointed Mr. Matthieu Bazil as its new CEO, effective immediately. Mr. Bazil will be based from the Aqua Lung Group offices in Carros, France.
Bazil takes the helm as Aqua Lung continues on a path of global leadership in developing and bringing to market the best in scuba, swim, snorkel, and recreational paddle sport products. Bazil, a passionate watersports enthusiast and scuba diver, comes to Aqua Lung after highly successful engagements at Fox Racing, Oxbow, Boardriders Inc. (with global leadership roles at both DC Shoes and Quiksilver), and key account management with adidas.
“I have worked in the sports industry all my life and have sought out brands that are authentic and credible in their space and leaders in their industry. Aqua Lung fits this definition perfectly, being the pioneer of scuba diving, and each brand of the portfolio being the most authentic and credible player in their segment,” said Mr. Bazil.
The Aqua Lung Group is fully committed to evolving and innovating the absolute best products to inspire every type of water exploration, led by scuba brands Aqua Lung and Apeks Diving. The Group is also heavily invested in the world of swimming, with Aqua Sphere and a longstanding partnership with Michael Phelps around the MP Brand swimming line for competitive swimmers and triathletes.
“We will rely most on the strength of our assets, whether it’s the best to ever get in the pool in Michael Phelps, or the first family of the Oceans with Philippe and Ashlan Cousteau -- combining these iconic personalities with our incredibly capable internal teams and brands, we will push forward with truly remarkable next-generation products built by our dedicated experts worldwide. There is much on the horizon for the Aqua Lung Group and it is my honor to be joining this talented team,” concluded Mr. Bazil.
About the Aqua Lung Group
Aqua Lung pioneered the creation of modern diving equipment in 1943 when Captain Jacques-Yves Cousteau teamed with Emile Gagnan to develop the first “aqua-lung” that made underwater exploration possible. Today, the brand continues to be the leading global designer and manufacturer of dive and water sports gear. With a deep commitment to quality, research and testing, Aqua Lung has revolutionized the scuba diving experience by setting industry standards for scuba equipment in technology, comfort, safety and design. The company’s rich history as an expert in the dive and water sports industry has led to the demand of Aqua Lung equipment for recreational, swim, technical and military applications in more than 100 countries around the world, under the brand names Aqua Lung, MP Michael Phelps, Aqua Sphere, Apeks, O.ME.R, U.S. Divers, and Stohlquist. For more information, visit www.AquaLung.com , http://www.Facebook.com/AquaLungDivers .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910006162/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB and Vår Energi Expand Digital Collaboration to Scale Well and Integrated Field Development Planning28.5.2026 13:47:00 CEST | Press release
Agreement supports Vår Energi’s ambition to reduce time to first oil, building on multi-discipline, collaborative well planning workflows that reduce cycle times from months to days Global energy technology company SLB (NYSE: SLB) today announced an expanded collaboration with Vår Energi to scale well planning and integrated field development planning across its Norwegian Continental Shelf operations. With collaborative well planning already reducing cycle times from months to days and integrated field development planning expected to support similar benefits, the expanded deployment is designed to support faster, more consistent decision-making as operators work to sustain production from mature offshore assets while managing increasing development complexity. As part of the expanded collaboration, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well planning, subsea design, field development planning, and production in a cloud-native
Kinaxis Convenes Global Supply Chain Leaders at Kinexions North America to Advance Agentic AI and Decision Orchestration28.5.2026 13:00:00 CEST | Press release
Annual conference brings customers, partners, and industry leaders together to explore how enterprises are turning decisions into coordinated action Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, is set to host Kinexions North America kicking off next week from June 1-3 at The Cosmopolitan of Las Vegas. The company’s flagship conference will bring together global supply chain, business and technology leaders for three days of product innovation, customer insights, and peer networking as Kinaxis continues to advance its focus on AI-driven decision making across the supply chain industry. This year’s event will spotlight how organizations are applying agentic AI and orchestration, moving beyond insight to execution, and increasingly from decisions to coordinated action. Speakers from global organizations including Merck, Bristol Myers Squibb, Unilever, British American Tobacco, Qualcomm, ExxonMobil, The Hershey Company, Scotts Miracle-Gro, and
Amadeus Redefines Travel Advertising to Help Brands Capture Demand Earlier28.5.2026 13:00:00 CEST | Press release
Developed in collaboration with Accenture, the AI-powered platform helps travel brands make smarter advertising decisions earlier and drive profitable demand through greater control, transparency, efficiency and performance. Amadeus today introduced the Amadeus Travel Advertising Platform at its Advertising Summit in Nice, France. Leveraging Accenture’s agentic framework for campaign execution, the platform outlines a new approach designed to help travel companies make faster, smarter advertising decisions based on where demand is forming — not just where it has already converted. Travel advertising has become increasingly complex, fragmented across channels and often driven by historical performance signals that arrive too late to capture emerging demand. As travelers plan trips across AI chatbots, search, social, metasearch, content platforms and OTAs long before booking, travel brands face rising acquisition costs and growing pressure to prove return on investment. The Amadeus Trave
Compass Pathways Elects Kathleen Tregoning to Board of Directors28.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. “With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy, and patient access matters more
Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)28.5.2026 12:28:00 CEST | Press release
IND enables initiation of U.S. clinical development in PSP Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526387210/en/ “FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer. “We can now expand our clinical efforts in the U.S. to evaluate AZP2006’s potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies.” Dr. Artin Karapet, Chief Medical Officer, commented: “The FDA’s clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom